Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it

Page 3 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)TerminatedNCT06964165Phase 2Results posted
• Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid TumorsTerminatedNCT06560632Phase 1Results posted
• A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)CompletedNCT05763823Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
• Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsTerminatedNCT05571969Phase 1Results posted
• Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerTerminatedNCT05501548Phase 2Results posted
• Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingNCT05457257Phase 4Results posted
• Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped WorkingActive, not recruitingNCT05432791Phase 2/3Results posted
• RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT05405309Phase 1/2Results posted
• Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersCompletedNCT05379972Phase 2Results posted
• PARP Inhibition for Gliomas (PI-4G or π4g)TerminatedNCT05297864Phase 2Results posted
• Olaparib in Subjects With Advanced Pancreatic Acinar Cell CarcinomaTerminatedNCT05286827Phase 2Results posted
• A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerCompletedNCT05258747Phase 1Results posted
• A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive, not recruitingNCT05203445Phase 2Results posted
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active, not recruitingNCT05171816Phase 3Results posted
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsTerminatedNCT05169437Phase 2Results posted
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialActive, not recruitingNCT05142241Phase 2Results posted
• Letermovir for CMV Prevention After Lung TransplantationCompletedNCT05041426Phase 2Results posted
• Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminatedNCT04951492Phase 2Results posted
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseActive, not recruitingNCT04915755Phase 3Results posted
• Letermovir Use in Heart Transplant RecipientsCompletedNCT04904614Phase 4Results posted
• Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerTerminatedNCT04849364Phase 2Results posted
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.TerminatedNCT04840199Phase 2Results posted
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results posted
• Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedNCT04729387Phase 3Results posted
• A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerTerminatedNCT04690855Phase 2Results posted
• CATCH-R: A Rollover Study to Provide Continued Access to RucaparibCompletedNCT04676334Phase 3Results posted
• STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORSCompletedNCT04635631Phase 1Results posted
• A Study of Rucaparib and Nivolumab in People With LeiomyosarcomaActive, not recruitingNCT04624178Phase 2Results posted
• BrUOG 390: Neoadjuvant Treatment With TalazoparibTerminatedNCT04598321Phase 1Results posted
• Niraparib + Dostarlimab In BRCA Mutated Breast CancerActive, not recruitingNCT04584255Phase 2Results posted
• PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedNCT04556617Phase 1/2Results posted
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)TerminatedNCT04544995Phase 1Results posted
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)Active, not recruitingNCT04497844Phase 3Results posted
• Study of RP-3500, Camonsertib, in Advanced Solid TumorsCompletedNCT04497116Phase 1/2Results posted
• Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerCompletedNCT04493060Phase 2Results posted
• Pembrolizumab and Olaparib in Cervical Cancer PatientsTerminatedNCT04483544Phase 2Results posted
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT04475939Phase 3Results posted
• Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)CompletedNCT04456699Phase 3Results posted
• Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results posted
• Niraparib + Dostarlimab + RT in Pancreatic CancerCompletedNCT04409002Phase 2Results posted
• Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerTerminatedNCT04377087Phase 2Results posted
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminatedNCT04336943Phase 2Results posted
• Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results posted
• Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCCCompletedNCT04313504Phase 2Results posted
• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• Study of Pembrolizumab and Olaparib in Bile Duct CancerCompletedNCT04306367Phase 2Results posted
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results posted
• Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCompletedNCT04209686Phase 2Results posted
• PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersCompletedNCT04209595Phase 1/2Results posted
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingNCT04197713Phase 1Results posted
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedNCT04191135Phase 2Results posted
• Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness GenesCompletedNCT04187833Phase 2Results posted
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)CompletedNCT04173507Phase 2Results posted
• A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesTerminatedNCT04171700Phase 2Results posted
• TMZ + Olaparib for MGMT Hypermethylated Colorectal CancerCompletedNCT04166435Phase 2Results posted
• MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)CompletedNCT04129398Phase 3Results posted
• Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic SarcomaCompletedNCT04076579Phase 2Results posted
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
• Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedNCT04052204Phase 1/2Results posted
• Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsActive, not recruitingNCT04042831Phase 2Results posted
• Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringCompletedNCT04037254Phase 1/2Results posted
• Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsTerminatedNCT04030559Phase 2Results posted
• A Study of the Drugs Talazoparib and Temozolomide in Prostate CancerTerminatedNCT04019327Phase 1/2Results posted
• Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With CancerCompletedNCT03994211Phase 1Results posted
• Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03983993Phase 2Results posted
• A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)CompletedNCT03976362Phase 3Results posted
• Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)CompletedNCT03976323Phase 3Results posted
• Combination Rucaparib With Nivolumab in Small Cell Lung CarcinomaCompletedNCT03958045Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian CancerTerminatedNCT03955471Phase 2Results posted
• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingNCT03953898Phase 2Results posted
• Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)CompletedNCT03940586Phase 2Results posted
• Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)CompletedNCT03930615Phase 3Results posted
• A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerTerminatedNCT03901469Phase 2Results posted
• A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaActive, not recruitingNCT03880019Phase 2Results posted
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingNCT03878095Phase 2Results posted
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedNCT03875313Phase 1/2Results posted
• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingNCT03842228Phase 1Results posted
• A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric AdenocarcinomaTerminatedNCT03840967Phase 2Results posted
• A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.CompletedNCT03840200Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedNCT03834519Phase 3Results posted
• A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)TerminatedNCT03824704Phase 2Results posted
• A Study of Olaparib and Durvalumab in Prostate CancerTerminatedNCT03810105Phase 2Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results posted
• Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active, not recruitingNCT03775486Phase 2Results posted
• Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerCompletedNCT03759600Phase 2Results posted
• Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerCompletedNCT03759587Phase 2Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingNCT03748641Phase 3Results posted
• Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)Active, not recruitingNCT03742895Phase 2Results posted
• Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)CompletedNCT03740165Phase 3Results posted

← Poly(ADP-ribose) Polymerase Inhibitors overview